LPCN Lipocine Inc
Company Analysis
Latest News
🟢 Lipocine is trading 23.3% up today with no clear catalyst identified
Lipocine is trading 23.33% up at $2.59, with no clear catalyst identified. - The price has moved sharply from the October 6 close of $2.10. - Searches found no...
🟢 Lipocine is trading 23.4% up in pre-market — catalyst unclear
Lipocine is trading 23.4% up at $2.59 before the October 7, 2026 open, with the catalyst unclear. - The October 6 close was $2.10. - The latest notable company...
🟢 Lipocine is trading 5.8% up in pre-market with no clear catalyst identified
Lipocine is trading 5.8% up in pre-market at $2.19 on October 2, with no clear company-specific catalyst identified for the move. - Shares closed at $2.07 on...
🔴 Lipocine is trading 5% down; no clear company-specific catalyst
Lipocine is trading at $2.08, down 5.45%, with no clear Lipocine-specific negative catalyst identified for October 1. - A director’s reported September 28...
🟢 Lipocine is trading 5.74% up today
Lipocine is trading at $2.21, up 5.74%; no clear company-specific catalyst surfaced in the available news search for September 29, 2026. - The reported Phase 3...
🔴 Lipocine is trading 5.1% down today with no clear catalyst identified
Lipocine is trading 5.1% down at $2.12, with no clearly attributable company-specific catalyst identified for September 22, 2026. - The latest company...
🔴 Lipocine is trading 5.29% down today amid broad market weakness
Lipocine is trading at $2.15, with a -5.29% change amid a broader risk-off session. - The S&P 500 is down 0.73%, while the Nasdaq Composite is down 0.93%. -...
Lipocine Initiates Pivotal Phase 3 Study of LPCN 1154 for Postpartum Depression
Lipocine Inc. announced the initiation of its BLOOM Phase 3 clinical study for LPCN 1154, an investigational oral treatment for postpartum depression (PPD)....
🟢 Lipocine is trading 8.81% up in pre-market; catalyst unclear
Lipocine is trading at $2.45, up +8.81% in pre-market, with no clear catalyst identified. - On September 10, 2026, management announced it will present at the...
🔴 Lipocine is trading 7% down in pre-market with no clear company-specific catalyst identified
Lipocine is trading at $2.28 (-6.94%) after no clear company-specific announcement was identified for September 8, 2026. • Broader sentiment is moderately...
🔴 Lipocine is trading 6.12% down in after-hours trading with no clear catalyst identified
Lipocine is trading 6.12% down at $2.30 after-hours on September 4, 2026, with no clear catalyst identified. - No company-specific announcement, filing,...
🟢 Lipocine is trading 6.16% up today amid 2.75% gain in biotech ETF XBI
Lipocine is trading at $2.50, up +6.16%, alongside a 2.75% gain in biotech ETF XBI. - No reliable September 3 company-specific announcement, filing, earnings...
🔴 Lipocine is trading 8.1% down in pre-market; catalyst remains unclear
Lipocine is trading at $2.10 (-8.10%) in pre-market, with the catalyst remaining unclear. - No reliable September 2, 2026 company-specific announcement,...
🟢 Lipocine is trading 5% up today as biotech sector rallies
Lipocine is trading at $2.26 (+5.12%) on August 27, 2026, alongside a strong biotech-sector rally. - The SPDR S&P Biotech ETF (XBI) was reported up 2.06%,...
🟢 Lipocine is trading 5.35% up today on broader biotech strength
Lipocine is trading 5.35% up at $2.27, supported mainly by broader biotech-sector strength. - Biotech ETF XBI is up 2.06% during the regular session,...
🟢 Lipocine is trading 6.8% up today in pre-market amid possible broader risk-on sentiment
Lipocine is trading 6.8% up at $2.20 after closing at $2.06 on August 24, 2026, possibly reflecting broader risk-on sentiment. - No August 25 company-specific...
🟢 Lipocine is trading 5.83% up today with no clear company-specific catalyst
Lipocine is trading 5.83% up now at $2.18, with no clear company-specific catalyst identified for August 14, 2026. - The latest identified corporate...
🟢 Lipocine is trading 8% up today as softer rate-hike expectations support equities
Lipocine is trading at $2.22, up 7.95% on August 13, 2026, as broader risk appetite supports equities after softer rate-hike expectations following CPI. - The...
Lipocine's second quarter net loss widens to $2.6M as it plans a new trial for its PPD drug after a Phase 3 failure.
Lipocine reported a second quarter net loss of $2.6 million, or ($0.32) per share, compared to a net loss of $2.2 million, or ($0.41) per share, in the prior...
🟢 Lipocine is trading 6.13% up today following Q2 results and board appointment
Lipocine is trading at $2.26 (+6.13%) after reporting second-quarter 2026 results and announcing a key addition to its board of directors. • The company...